{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"11.8","value":"5.4"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"33.0","value":"10.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"PFS was defined as the time from the first dose of study treatment to the first documentation of objective PD or to death on study due to any cause, whichever came first. Progressive disease was defined by a 20% or more increase in the SLD of target lesions relative to baseline or the smallest SLD (nadir) recorded since first dose. In addition to the relative increase of 20%, SLD must also demonstrate an absolute increase of at least 5 mm (\\>= 5 mm) relative to baseline or the smallest SLD (nadir) recorded since the first dose. Results presented here were based on independent central review.","dispersionType":"95% Confidence Interval","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"},{"description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.","id":"OG001","title":"ROS1 Positive Population (Phase 1)"}],"paramType":"MEDIAN","populationDescription":"PFS analysis set included all participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922.","reportingStatus":"POSTED","timeFrame":"From start of study treatment to first documentation of PD or to death due to any cause, whichever occurred first (maximum of 8 years approximately)","title":"Progression-Free Survival (PFS) (Phase 1)","type":"SECONDARY","unitOfMeasure":"Months"}